Tesaro offers patients early access to investigational anticancer agent niraparib

17 January 2017
2019_biotech_test_vial_discovery_big

Tesaro (Nasdaq: TSRO) is launching a managed access program in the USA for its investigational oncology treatment niraparib.

The scheme, which is also known as an expanded access program (EAP), is being administered by British pharmaceuticals and services firm Clinigen Group (AIM: CLIN).

EAP programs allow patients with life-threatening conditions to access late-stage investigational drugs, before they have received regulatory approval. They can also help guide future development of a therapy, through anecdotal evidence of its effects.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology